Vaccine value profile for norovirus
Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved..
Norovirus is attributed to nearly 1 out of every 5 episodes of diarrheal disease globally and is estimated to cause approximately 200,000 deaths annually worldwide, with 70,000 or more among children in developing countries. Noroviruses remain a leading cause of sporadic disease and outbreaks of acute gastroenteritis even in industrialized settings, highlighting that improved hygiene and sanitation alone may not be fully effective in controlling norovirus. Strengths in global progress towards a Norovirus vaccine include a diverse though not deep pipeline which includes multiple approaches, including some with proven technology platforms (e.g., VLP-based HPV vaccines). However, several gaps in knowledge persist, including a fulsome mechanistic understanding of how the virus attaches to human host cells, internalizes, and induces disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 Suppl 2 |
|---|---|
| Enthalten in: |
Vaccine - 41 Suppl 2(2023) vom: 03. Nov., Seite S134-S152 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Armah, George [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Global Health |
|---|
| Anmerkungen: |
Date Completed 13.11.2023 Date Revised 14.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.vaccine.2023.03.034 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364433507 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364433507 | ||
| 003 | DE-627 | ||
| 005 | 20231227131943.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.vaccine.2023.03.034 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1226.xml |
| 035 | |a (DE-627)NLM364433507 | ||
| 035 | |a (NLM)37951692 | ||
| 035 | |a (PII)S0264-410X(23)00318-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Armah, George |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Vaccine value profile for norovirus |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.11.2023 | ||
| 500 | |a Date Revised 14.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a Norovirus is attributed to nearly 1 out of every 5 episodes of diarrheal disease globally and is estimated to cause approximately 200,000 deaths annually worldwide, with 70,000 or more among children in developing countries. Noroviruses remain a leading cause of sporadic disease and outbreaks of acute gastroenteritis even in industrialized settings, highlighting that improved hygiene and sanitation alone may not be fully effective in controlling norovirus. Strengths in global progress towards a Norovirus vaccine include a diverse though not deep pipeline which includes multiple approaches, including some with proven technology platforms (e.g., VLP-based HPV vaccines). However, several gaps in knowledge persist, including a fulsome mechanistic understanding of how the virus attaches to human host cells, internalizes, and induces disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Global Health | |
| 650 | 4 | |a Policy | |
| 650 | 4 | |a Vaccine value | |
| 650 | 4 | |a Vaccines | |
| 650 | 7 | |a Viral Vaccines |2 NLM | |
| 700 | 1 | |a Lopman, Ben A |e verfasserin |4 aut | |
| 700 | 1 | |a Vinjé, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a O'Ryan, Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a Lanata, Claudio F |e verfasserin |4 aut | |
| 700 | 1 | |a Groome, Michelle |e verfasserin |4 aut | |
| 700 | 1 | |a Ovitt, Jared |e verfasserin |4 aut | |
| 700 | 1 | |a Marshall, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Sajewski, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Riddle, Mark S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccine |d 1985 |g 41 Suppl 2(2023) vom: 03. Nov., Seite S134-S152 |w (DE-627)NLM012600105 |x 1873-2518 |7 nnns |
| 773 | 1 | 8 | |g volume:41 Suppl 2 |g year:2023 |g day:03 |g month:11 |g pages:S134-S152 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.vaccine.2023.03.034 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 Suppl 2 |j 2023 |b 03 |c 11 |h S134-S152 | ||